Skip to content
AwardedGermanyGoodsFramework agreement

Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V i. V. m § 130c Abs. 1 SGB V zum Wirkstoff Depemokimab

Published
Published 12 May 2026

Overview

AOK Baden-Württemberg has concluded a pharmaceutical rebate agreement with GlaxoSmithKline GmbH & Co. KG for the active ingredient Depemokimab (Exdensur®) under German social security law provisions § 130a Abs. 8 SGB V and § 130c Abs. 1 SGB V. The agreement was awarded on 28 April 2026, with the exact contract value dependent on unknown factors and reported as a notional amount based on current threshold values.

Key details

Country
Germany
Status
Awarded
Category
Goods
Procedure
Direct
Contract type
Framework agreement
Published
12 May 2026
Classification (CPV)
Pharmaceutical products

Award outcome

Award date
28 April 2026
Contract period
1 May 2026 → 30 April 2028
Winner
  • GlaxoSmithKline GmbH & Co. KG

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    11 May 2026

Contracting authority

  • AOK Baden-Württemberg

    Procuring entity

    Stuttgart, Germany

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V i. V. m § 130c Abs. 1 SGB V zum Wirkstoff Depemokimab — won by GlaxoSmithKline GmbH & Co. KG — Skim